Researchers reported a shared vulnerability across shifting triple-negative breast cancer phenotypic states: DNA damage tolerance enzymes including POLζ and CHK1. Blocking these targets, alone or with Olaparib, overcomes chemoresistance in laboratory experiments. The study adds to a growing line of work treating resistance not as a single mechanism but as a network of adaptive pathways. For drug developers, the implication is to evaluate combination rationales that intercept the tolerance programs cells rely on during chemotherapy pressure.